Immunovant Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Eric Venker
Chief executive officer
US$55.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.5yrs |
| Board average tenure | 6yrs |
Recent management updates
Recent updates
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement
Dec 12We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Jul 22
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
Mar 19Immunovant, Inc.'s (NASDAQ:IMVT) Intrinsic Value Is Potentially 97% Above Its Share Price
Feb 06Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study
Dec 27Immunovant: Switching Lead Candidates Increases Risk
Oct 14Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive
Jun 27Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
Apr 04Immunovant: An Intriguing And Developing Story
Jan 25Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset
Oct 17Immunovant stock down on raising $75M though equity capital
Oct 04CEO
Eric Venker (38 yo)
Dr. Eric Venker, M.D., Pharm D., has been Chief Executive Officer at Immunovant, Inc. since April 18, 2025 and serves as its Director since February 18, 2020. Dr. Venker served as Chief Operating Officer o...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairperson of the Board | 6yrs | US$4.93m | 0.0099% $ 512.3k | |
| CEO & Director | less than a year | US$55.00k | no data | |
| Chief Operating Officer | 1.1yrs | US$6.19m | 0.0073% $ 380.5k | |
| Chief Legal Officer & Corporate Secretary | 1yr | US$6.29m | 0.0082% $ 427.2k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Technology Officer | 2.7yrs | US$4.04m | no data | |
| Senior Vice President of Human Resources | no data | no data | no data | |
| Senior Vice President of Strategic Finance | no data | no data | no data | |
| Senior Vice President of Program & Alliance Management | no data | no data | no data | |
| Senior Vice President of Regulatory Affairs | no data | no data | no data | |
| Senior VP & Global Head of Quality | 1.9yrs | no data | no data | |
| Senior Vice President of Biostatistics | 1.9yrs | no data | no data |
Experienced Management: IMVT's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairperson of the Board | 6yrs | US$4.93m | 0.0099% $ 512.3k | |
| CEO & Director | 5.8yrs | US$55.00k | no data | |
| Director | 6.2yrs | US$530.04k | 0.0015% $ 79.4k | |
| Independent Director | 6.2yrs | US$517.54k | 0.020% $ 1.0m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 6yrs | US$520.04k | 0.0066% $ 341.0k | |
| Independent Director | less than a year | no data | no data |
Experienced Board: IMVT's board of directors are considered experienced (6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/30 14:54 |
| End of Day Share Price | 2025/12/29 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immunovant, Inc. is covered by 22 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| Louise Chen | Cantor Fitzgerald & Co. |